Physician profile
Flora Ann Gorham
NPI 1063183168
$3,059.48
in general payments reported to CMS, 2019-2025
32 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $1,029 · 2023: $576 · 2024: $132 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $560.20 | 2021-2025 | |
| Lilly USA, LLC | $396.48 | 2022-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $263.38 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Antares Pharma, INC. | $253.73 | 2021-2025 | Xyosted |
| Novo Nordisk INC | $243.08 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $193.76 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Pfizer INC. | $125.50 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.41 | 2021-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $105.27 | 2022-2025 | Seglentis, Livalo, Zoryve |
| Vanda Pharmaceuticals INC. | $88.71 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.49 | 2022-2025 | |
| Eisai INC. | $51.09 | 2025 | |
| Janssen Pharmaceuticals, INC | $50.88 | 2021-2022 | |
| Mylan Specialty L.P. | $48.15 | 2023-2024 | Yupelri |
| Exact Sciences Corporation | $44.58 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $44.17 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.80 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.42 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $36.19 | 2025 | Voquezna |
| Fidia Pharma USA INC. | $30.20 | 2025 | Hymovis |
| Sumitomo Pharma America, INC. | $29.34 | 2023-2024 | Gemtesa |
| Currax Pharmaceuticals LLC | $28.10 | 2021 | |
| Vistapharm, INC. | $27.98 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $27.64 | 2025 | Rexulti |
| Nevro Corp. | $24.58 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $23.56 | 2025 | |
| Horizon Therapeutics Plc | $20.49 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.56 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.97 | 2022 | |
| Clarus Therapeutics INC. | $15.66 | 2021 | |
| Axsome Therapeutics, INC. | $14.42 | 2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Flora Gorham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.